# Teduglutide (GLP-2): Evidence, Mechanism & Status

> A clinical monograph on teduglutide — the GLP-2 receptor agonist FDA-approved for short bowel syndrome with intestinal failure. Grade A RCT evidence for SBS-IF, a mandated neoplasia-surveillance burden, and unproven 'leaky-gut' hype.

*Published 2026-06-30 · Updated 2026-07-01 · By Marcus Feld, PharmD, BCPS*

The short answer
Teduglutide is a genuine, **RCT-proven, disease-modifying** GLP-2 receptor agonist — but for a narrow population: **short bowel syndrome with intestinal failure (SBS-IF)** dependent on parenteral support. There the evidence is **Grade A**.[1](https://peptidevox.com/#r1)[3](https://peptidevox.com/#r3) It is FDA-approved (Gattex), but carries a mandated colonoscopy-surveillance burden for accelerated neoplastic growth.[15](https://peptidevox.com/#r15) Its barrier-strengthening biology is frequently invoked for 'leaky gut,' but that application is **Grade C (preclinical only)**.[12](https://peptidevox.com/#r12)

Teduglutide (Gattex in the US, Revestive in the EU) is a recombinant 33-amino-acid analog of glucagon-like peptide-2 (GLP-2), the intestinotrophic gut hormone that drives mucosal growth and absorptive adaptation. It is the first and best-evidenced growth-factor therapy for short bowel syndrome with intestinal failure — and it is also a frequent reference point in 'gut-repair' and leaky-gut conversations where its evidence does not reach.[2](https://peptidevox.com/#r2) This monograph separates the two.

*This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Teduglutide is a prescription biologic administered under specialist gastroenterology and nutrition-support supervision with mandatory endoscopic cancer surveillance. Dosing figures are reported strictly as published in trials and the FDA label for completeness — not as recommendations. Consult a licensed clinician before any health decision.*

## What is teduglutide and how does it work?

Teduglutide is a recombinant 33-amino-acid peptide analog of native human GLP-2. It differs from the endogenous hormone by a single substitution — glycine for alanine at position 2 of the N-terminus — which confers resistance to dipeptidyl peptidase-4 (DPP-4) cleavage and extends the half-life from native GLP-2's roughly 7 minutes to about 2 hours, enabling once-daily dosing.[10](https://peptidevox.com/#r10)[2](https://peptidevox.com/#r2)

GLP-2 is secreted by enteroendocrine L-cells of the distal ileum and colon in response to luminal nutrients, and acts on GLP-2 receptors expressed on intestinal subepithelial myofibroblasts, enteric neurons and enteroendocrine cells. Receptor activation triggers downstream mediators — insulin-like growth factor-1 (IGF-1), nitric oxide and keratinocyte growth factor — that drive crypt-cell proliferation, reduce enterocyte apoptosis, and expand intestinal stem-cell and Paneth-cell populations.[2](https://peptidevox.com/#r2)[12](https://peptidevox.com/#r12) The net intestinotrophic effect is increased villus height and crypt depth — greater mucosal absorptive surface area — plus increased intestinal and portal blood flow, slowed gastric emptying and secretion, and strengthened tight-junction barrier integrity.[10](https://peptidevox.com/#r10)[14](https://peptidevox.com/#r14) Administered subcutaneously, teduglutide reaches peak plasma concentration in roughly 3-5 hours. A useful pharmacodynamic confirmation of mucosal growth is plasma citrulline, a biomarker of functional enterocyte mass, which rises with treatment.[7](https://peptidevox.com/#r7)

## What is the evidence by indication?

The headline contrast is that teduglutide is one of the few peptides in this encyclopedia with completed, pivotal human randomized controlled trials — but only for SBS-IF. The detailed trial registrations and protocols sit on [ClinicalTrials.gov](https://clinicaltrials.gov/) alongside the published reports below.

  Teduglutide evidence by indication

    IndicationBest evidenceGrade

    Short bowel syndrome with intestinal failure (adults)Two pivotal Phase 3 RCTs (Jeppesen 2011; STEPS 2012) + long-term extensionsA (human RCT)
    SBS-IF (children >=1 year)Randomized Phase 3 (Kocoshis 2020) + open-label workA (human RCT)
    Crohn's-disease-related SBS-IFSmall mixed human cohorts / case series within the SBS indicationB (human cohort)
    Leaky gut / IBD barrier therapy (non-SBS)Caco-2 cell & mechanistic models; no qualifying efficacy RCTC (preclinical)

The adult Phase 3 data are the foundation. In Jeppesen's randomized, double-blind, placebo-controlled trial (n approximately 83, 24 weeks), clinical response — a >=20% reduction in parenteral support — reached 46% at 0.05 mg/kg/day versus 6% on placebo (p=0.005); the higher 0.1 mg/kg arm was not significantly different from placebo.[1](https://peptidevox.com/#r1)[2](https://peptidevox.com/#r2) STEPS, the largest double-blind randomized SBS-IF trial (n=86, 24 weeks), used a protocolized parenteral-support-reduction algorithm: 63% of teduglutide patients versus 30% of placebo achieved a 20-100% reduction in parenteral-support volume (p=0.002), with mean reduction of 4.4 L/week on teduglutide versus 2.3 L/week on placebo, and more patients achieving at least one day per week off parenteral support (54% versus 23%) — with no excess of serious adverse events.[3](https://peptidevox.com/#r3)[2](https://peptidevox.com/#r2)

The long-term open-label extensions are what make the case clinically meaningful. Of 39 teduglutide patients followed through the 2-year STEPS-2 extension, 8 achieved full enteral autonomy — complete parenteral-support independence — with time-to-weaning of 28-115 weeks; lower baseline parenteral-support volume (=20% parenteral-support reduction was met by 54.2% (0.025 mg/kg), 69.2% (0.05 mg/kg) and just 11.1% (standard of care), with both doses significantly reducing parenteral-support volume, calories and infusion days, and raising plasma citrulline; enteral autonomy occurred in 8.3% and 11.5% of the dose groups versus 0% of standard of care.[7](https://peptidevox.com/#r7)[8](https://peptidevox.com/#r8) Retrospective real-world series corroborate the trial efficacy, with roughly 67% achieving a >=20% reduction and about 30% reaching enteral autonomy.[9](https://peptidevox.com/#r9)

Proven vs hyped
Proven in humans: meaningful, durable reduction of parenteral-support dependence in SBS-IF, with a real subset reaching full enteral autonomy. Hyped: 'leaky-gut,' general gut-repair and athletic-recovery claims, which extrapolate from barrier-biology cell models with no qualifying human efficacy trial.[12](https://peptidevox.com/#r12)[13](https://peptidevox.com/#r13)

## What doses appear in the literature?

Reported strictly as information, not a protocol. Per the FDA label and pivotal trials, the dose is 0.05 mg/kg subcutaneously once daily, into alternating sites (thigh, arm and abdominal quadrants), reconstituted from lyophilized powder per the supplied diluent and Instructions for Use.[15](https://peptidevox.com/#r15)[10](https://peptidevox.com/#r10) For moderate-to-severe renal impairment (CrCl =1 year uses the same weight-based 0.05 mg/kg/day, although the pediatric RCT also tested a lower 0.025 mg/kg/day arm.[7](https://peptidevox.com/#r7) The dose-finding work established 0.05 mg/kg/day as optimal; the higher 0.10 mg/kg/day arm did not consistently reach statistical significance.[2](https://peptidevox.com/#r2) Treatment requires a baseline colonoscopy or upper-GI endoscopy with polyp removal within 6 months of starting, plus periodic biliary and pancreatic labs, and reassessment of parenteral-support volume as absorption improves to avoid fluid overload.[18](https://peptidevox.com/#r18)

## How safe is teduglutide?

The principal warning is accelerated neoplastic growth. Because teduglutide is intestinotrophic, it can promote hyperplastic or neoplastic change: intestinal polyps occurred in trials, and postmarketing reports include colorectal, gastric and small-intestinal polyps. The label mandates colonoscopy or upper-GI endoscopy before treatment, at about 1 year, then roughly every 5 years (or more often), with discontinuation if colorectal or small-bowel cancer is diagnosed.[15](https://peptidevox.com/#r15)[17](https://peptidevox.com/#r17) Other warnings include intestinal or stomal obstruction, biliary and pancreatic disease (cholecystitis, cholangitis, cholelithiasis, pancreatitis), and fluid overload as absorption improves and parenteral fluid must be down-titrated.[15](https://peptidevox.com/#r15) Because it enhances mucosal absorption, teduglutide can increase uptake of concomitant oral drugs — a caution with narrow-therapeutic-index agents.[15](https://peptidevox.com/#r15)

The most common adverse reactions across trials and the label are abdominal pain and distension, nausea, vomiting, headache, injection-site reactions, peripheral edema, and — in stoma patients — gastrointestinal stoma complications; in the pediatric Phase 3 the most common treatment-emergent events were pyrexia and vomiting.[7](https://peptidevox.com/#r7)[15](https://peptidevox.com/#r15) Active gastrointestinal malignancy is an effective contraindication, and in patients with active non-GI malignancy or a history of GI cancer it is used only when benefit clearly outweighs risk.[15](https://peptidevox.com/#r15)

## What is the FDA and WADA status in 2026?

Teduglutide is an approved biologic, not a research chemical. Gattex was approved December 21, 2012 for adults with parenteral-support-dependent SBS and expanded in 2019 to pediatric patients aged 1 year and older; label revisions through 2024 retain the neoplasia-surveillance and obstruction and biliary warnings.[15](https://peptidevox.com/#r15)[16](https://peptidevox.com/#r16) It is orphan-drug designated, marketed by Takeda with a REMS-style safety program, and approved as Revestive in the EU and additional markets; regional pediatric and infant studies continue.[17](https://peptidevox.com/#r17)[20](https://peptidevox.com/#r20)[21](https://peptidevox.com/#r21) Because it is a defined, commercially available branded product, there is no evidence-based or regulatory basis for compounding it as a research peptide; any 'research-chemical' GLP-2 sold outside the approved supply chain is unapproved and unverified.

For athletes, teduglutide is not explicitly named on the WADA Prohibited List. It is a gut-restricted intestinotrophic agent with no recognized ergogenic or anabolic-systemic action — unlike GLP-1 agonists, which WADA placed on its Monitoring Program, GLP-2 analogs are not flagged as performance-relevant. Athletes with a medical need should still verify current status with their anti-doping authority.[19](https://peptidevox.com/#r19)

**Bottom line.** Teduglutide is a genuine, RCT-proven, disease-modifying therapy — but for a narrow population: short bowel syndrome with intestinal failure dependent on parenteral support, where the evidence is Grade A and biomarker-confirmed. The trade-off is a serious, label-mandated surveillance burden for accelerated neoplastic growth plus obstruction, fluid-overload and biliary/pancreatic risks, making it a specialist-managed drug rather than a casual gut-repair peptide. Its barrier-strengthening biology is frequently cited in leaky-gut and IBD conversations, but that application is Grade C — promising in principle, unproven in humans outside SBS. Regulatory facts here are current as of June 2026 and should be re-verified against the latest FDA label and WADA list.

---
Source: https://peptidevox.com/peptide-encyclopedia/glp-2-teduglutide
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt